Potentiates insulin signaling via chromodulin (low-molecular-weight chromium-binding substance, LMWCr) which amplifies insulin receptor tyrosine kinase activity
Enhances GLUT4 translocation to plasma membrane in insulin-sensitive tissues, improving cellular glucose uptake
Cofactor support for normal macronutrient (carbohydrate, protein, lipid) metabolism
May modulate hepatic gluconeogenesis and improve insulin sensitivity in insulin-resistant states
Molecular + tissue targets
Insulin receptor signaling
Glucose homeostasis pathway
Macronutrient metabolism enzymes
GLUT4 transporter trafficking
Dosage range
Adequate Intake (US/IOM): adult men 35 mcg/day, adult women 25 mcg/day. EFSA AI: 40 mcg/day adults. Supplemental ranges in glycemic-support clinical trials: 200-1000 mcg/day elemental chromium (commonly 200-600 mcg/day chromium picolinate). No established UL (insufficient data); intakes >1000 mcg/day reserved for clinical settings under supervision.
Safety notes
Trivalent chromium (Cr III) from food and supplements is considered low-toxicity at typical intakes. Hexavalent chromium (Cr VI) is a known carcinogen and is NOT used in supplements. Rare case reports of nephrotoxicity, hepatotoxicity, and rhabdomyolysis at high-dose long-term chromium picolinate (>600 mcg/day chronic). Potential interaction with antidiabetic drugs (additive hypoglycemic effect — monitor glucose). Caution in patients with renal or hepatic impairment. Pregnancy/lactation: stay within AI; supplementation beyond AI not recommended without clinical indication. Avoid in patients with chromate allergy.
Cross-market regulatory status
🇺🇸 FDA
United States (FDA): Chromium has NO SSA (Significant Scientific Agreement) authorized health claim under 21 CFR Part 101 Subpart E. Marketed as a dietary supplement under DSHEA (1994); structure/function claims permitted (e.g., "helps maintain healthy blood sugar levels already within normal range") with mandatory DSHEA disclaimer "This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease." FDA issued a Qualified Health Claim (NOT SSA) via Letter of Enforcement Discretion dated 2005-08-25 (Docket No. 2004Q-0144) for chromium picolinate and reduced risk of insulin resistance / type 2 diabetes: "One small study suggests that chromium picolinate may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes. FDA concludes, however, that the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain." Conditions: dietary supplements meeting "high" chromium level (>= 24 mcg per RACC). This is enforcement discretion, not an authorized SSA claim.
🇪🇺 EFSA
European Union (EFSA / EU Reg 432/2012): Two authorized Article 13(1) general function health claims for chromium per the EU Register and Annex of Commission Regulation (EU) No 432/2012. Conditions: the claim may be used only for food which is at least a source of trivalent chromium per Annex of Reg 1924/2006 (>= 15% of NRV per 100 g/mL or per portion for foods, or per daily portion for supplements). EFSA Scientific Opinions: 2010;8(10):1732 and 2011;9(6):2203. Trivalent chromium only (Cr VI not permitted).
🇧🇷 ANVISA
Brazil (ANVISA): Cromo (chromium) is permitted as a constituent of suplementos alimentares under Instrução Normativa IN nº 28/2018 (Anexo II — limites de uso) and authorized functional claims are listed in Anexo V. Exact Portuguese verbatim wording of the "O cromo auxilia..." claim(s) requires direct confirmation from the official BVSMS PDF text — ANVISA authorized_claims intentionally absent pending official PDF verification. Subsequent updates (e.g., IN nº 304/2024) may revise the list and should be cross-checked before use on Brazilian SKU labels.
Authorized claims · verbatim (2)
Direct quotes from each jurisdiction's framework · never paraphrased · with framework reference and conditions of use.
🇪🇺 EFSA · 2 claims
Reg 432/2012
Chromium contributes to normal macronutrient metabolism
Conditions: The claim may be used only for food which is at least a source of trivalent chromium as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006.
Reg 432/2012
Chromium contributes to the maintenance of normal blood glucose levels
Conditions: The claim may be used only for food which is at least a source of trivalent chromium as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006.
Common use cases
Glycemic support in adults with type 2 diabetes or impaired glucose tolerance
General macronutrient metabolism support in supplement formulations
Adjunct in metabolic syndrome / insulin resistance regimens
Body composition / weight management blends (claim evidence weak — use cautiously)
